THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Mallinckrodt-CE-Cert

More Like This

PR Newswire associated0

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings

PR Newswire associated0

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

PR Newswire associated0

TOOsonix receives MDR CE Mark for its new oncology and dermatology device

PR Newswire associated0

EYE PCR Receives CE Mark for fixOflex Endocapsular Device, Enabling European Market Introduction

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells

PR Newswire associated0

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe